Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and AchondroplasiaRobert L. Hudkins, Daniel C. Bensen, Alexandra Balcer et al.|Journal of Medicinal Chemistry|2024Cited by 28
Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance MutationsRobert L. Hudkins, Daniel C. Bensen, Samhita Iyer et al.|Journal of Medicinal Chemistry|2026Cited by 0